NeRRe Therapeutics, a clinical stage company developing a portfolio of neurokinin (NK) receptor antagonists, based at the Stevenage Biosciences Catalyst in the UK, says Dr Mary Kerr is joining the company as CEO at the beginning of next month.
Dr Kerr has spent the majority of her career on the R&D/commercial interface in global strategy and regional operational roles at GSK and predecessor companies, predominantly in the speciality and orphan drug areas. She has also been appointed an Operating Partner at Advent Life Sciences, one of NeRRe's investors.
Most recently Dr Kerr was Senior Vice President and Global Franchise Leader for GSK’s Immunoinflammation and Infectious Diseases portfolio. Before that she was a founding member in the executive team of ViiV Healthcare, the independent, HIV company that combines the HIV expertise of GSK, Pfizer and Shionogi, where she led, revitalised and grew the business in Europe.
